JPS6341890B2 - - Google Patents

Info

Publication number
JPS6341890B2
JPS6341890B2 JP53059873A JP5987378A JPS6341890B2 JP S6341890 B2 JPS6341890 B2 JP S6341890B2 JP 53059873 A JP53059873 A JP 53059873A JP 5987378 A JP5987378 A JP 5987378A JP S6341890 B2 JPS6341890 B2 JP S6341890B2
Authority
JP
Japan
Prior art keywords
fibrinogen
injected
rats
plasma
carrageenan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP53059873A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5417107A (en
Inventor
Ruuensutorotsuto Bauaa Geeruharuto
Sheereru Rainaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MATSUKUSU PURANKU G TSUA FUERUDERUNKU DERU UITSUSENSHAFUTEN EE FUAU
Original Assignee
MATSUKUSU PURANKU G TSUA FUERUDERUNKU DERU UITSUSENSHAFUTEN EE FUAU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19772722769 external-priority patent/DE2722769C3/de
Priority claimed from DE2750920A external-priority patent/DE2750920C3/de
Application filed by MATSUKUSU PURANKU G TSUA FUERUDERUNKU DERU UITSUSENSHAFUTEN EE FUAU filed Critical MATSUKUSU PURANKU G TSUA FUERUDERUNKU DERU UITSUSENSHAFUTEN EE FUAU
Publication of JPS5417107A publication Critical patent/JPS5417107A/ja
Publication of JPS6341890B2 publication Critical patent/JPS6341890B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP5987378A 1977-05-20 1978-05-19 Treating agent of abnormal progress Granted JPS5417107A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19772722769 DE2722769C3 (de) 1977-05-20 1977-05-20 Verwendung von Fibrinogen
DE2750920A DE2750920C3 (de) 1977-11-15 1977-11-15 Verwendung von Fibrinopeptiden A und B

Publications (2)

Publication Number Publication Date
JPS5417107A JPS5417107A (en) 1979-02-08
JPS6341890B2 true JPS6341890B2 (enExample) 1988-08-19

Family

ID=25772044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5987378A Granted JPS5417107A (en) 1977-05-20 1978-05-19 Treating agent of abnormal progress

Country Status (4)

Country Link
US (1) US4215109A (enExample)
JP (1) JPS5417107A (enExample)
CH (1) CH644762A5 (enExample)
GB (1) GB1603244A (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5104639A (en) * 1980-01-14 1992-04-14 Esa, Inc. Method for biological testing and/or developing pharmaceuticals for treatment of disorders using electrochromatography
US6333160B1 (en) 1988-08-31 2001-12-25 Keiji Tamura Method and specific diagnostic system for objectively assessing and monitoring the relative homeostasis and health of animals
ES2114654T3 (es) * 1993-06-08 1998-06-01 Vertex Pharma Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.
US7605132B2 (en) * 2001-08-29 2009-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
US7528227B2 (en) * 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3973001A (en) * 1954-04-27 1976-08-03 Solco Basel Ag Tissue cell stimulating blood extracts
US2847349A (en) * 1954-05-27 1958-08-12 Ortho Pharma Corp Plasma preparation
US2847348A (en) * 1954-05-27 1958-08-12 Ortho Pharma Corp Plasma fractionation and product therefrom
US3466368A (en) * 1967-06-02 1969-09-09 Us Health Education & Welfare Cleavage of human gamma globulin by means of cyanogen bromide
AT275038B (de) * 1967-11-15 1969-10-10 Immuno Ag Verfahren zur Gewinnung von reinem Blutalbumin aus Hämopigmente enthaltenden Proteinlösungen
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
US3664994A (en) * 1969-06-30 1972-05-23 Upjohn Co Process for separating horse gamma globulin fractions by chromatography
US3763135A (en) * 1971-11-08 1973-10-02 Baxter Laboratories Inc Gamma globulin production from cohn fraction iii using polyethylene glycol
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US3808189A (en) * 1973-03-15 1974-04-30 American Cyanamid Co Isolation of gamma globulin preparations enriched in iga and igm using polyethylene glycol
US3893990A (en) * 1973-04-05 1975-07-08 Baxter Laboratories Inc Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene
US3893991A (en) * 1973-04-05 1975-07-08 Baxter Laboratories Inc Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US3973002A (en) * 1974-04-12 1976-08-03 E. R. Squibb & Sons, Inc. Antihemophilic factor
JPS5176418A (en) * 1974-12-26 1976-07-02 Teijin Ltd Menekiguroburinno seizoho
DE2500076C3 (de) * 1975-01-02 1982-11-18 SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld Verfahren zur Gewinnung von intravenös-verträglichen Gammaglobulinen
CA1064396A (en) * 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4087415A (en) * 1976-06-09 1978-05-02 William L. Wilson Antithrombin III
US4081432A (en) * 1977-07-25 1978-03-28 Monsanto Company Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers

Also Published As

Publication number Publication date
GB1603244A (en) 1981-11-18
US4215109A (en) 1980-07-29
JPS5417107A (en) 1979-02-08
CH644762A5 (de) 1984-08-31

Similar Documents

Publication Publication Date Title
Silver et al. Arachidonic acid causes sudden death in rabbits
US5508265A (en) Therapeutic uses of actin-binding compounds
Kumar et al. Angiogenesis factor from human myocardial infarcts
Opelz et al. Suppression of lymphocyte transformation by aspirin
US6624141B1 (en) Protamine fragment compositions and methods of use
Simon et al. Alteration of bile canalicular enzymes in cholestasis. A possible cause of bile secretory failure
HU206988B (en) Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient
Rothstein et al. Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5).
Perper et al. Leukocyte chemotaxis in vivo. II. Analysis of the selective inhibition of neutrophil or mononuclear cell accumulation
PT86393B (pt) Processo para a preparacao de agentes terapeuticos e profilaticos contendo proteina tecidual pp4 e para a purificacao desta proteina
Ohlsson Collagenase and elastase released during peritonitis are complexed by plasma protease inhibitors
JPS6341890B2 (enExample)
Kline Plasminogen
Dubey et al. A Screening Models of (In Vivo And In Vitro) Used for the Study of Hepatoprotective Agents.
Kajita et al. Evidence for in vivo degradation of C3a anaphylatoxin by mast cell chymase. I. Nonspecific activation of rat peritoneal mast cells by C3ades Arg
EP0758656B1 (en) Immunoglobulin activated by mixing with a histamine component
JPS62255430A (ja) 哺乳動物の脈管病を治療する方法
Simmons et al. Suppression of active but not passive autoimmune encephalomyelitis by dual cyclo‐oxygenase and 5‐lipoxygenase inhibition
Mackenzie et al. Rapid renal failure in a case of multiple myeloma: the role of Bence Jones proteins
Hayashi et al. Higher Susceptibility to Thiol Compounds of Protease of Healing Sites in Arthus-type Inflammation and its Biological Significance
Vélez‐García et al. Long‐term follow‐up and therapy in multiple myeloma
Lundgren et al. Is there an intestinal natriuretic factor?
Türker et al. High degree of conversion of angiotensin I to angiotensin II in the mesenteric circulation of the isolated perfused terminal ileum of the cat
EDDELAND et al. Secretin/cholecystokinin-stimulated secretion of trypsinogen and trypsin inhibitor in pure human pancreatic juice collected by endoscopic retrograde catheterization
JPH08782B2 (ja) 抗炎症剤